Cargando…

The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line

Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which...

Descripción completa

Detalles Bibliográficos
Autores principales: Zduniak, Krzysztof, Gdesz-Birula, Katarzyna, Woźniak, Marta, Duś-Szachniewicz, Kamila, Ziółkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664331/
https://www.ncbi.nlm.nih.gov/pubmed/33171718
http://dx.doi.org/10.3390/molecules25215184
_version_ 1783609822717935616
author Zduniak, Krzysztof
Gdesz-Birula, Katarzyna
Woźniak, Marta
Duś-Szachniewicz, Kamila
Ziółkowski, Piotr
author_facet Zduniak, Krzysztof
Gdesz-Birula, Katarzyna
Woźniak, Marta
Duś-Szachniewicz, Kamila
Ziółkowski, Piotr
author_sort Zduniak, Krzysztof
collection PubMed
description Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which is a drug presently used in the treatment of plasma cell myeloma. TMD and PDT share similar modes of action in neoplastic conditions. Using 4T1 murine breast carcinoma and 2H11 murine endothelial cells lines as an experimental tumor model, we tested 5-ALA-PDT and TMD combination in terms of cytotoxicity, apoptosis, Vascular Endothelial Growth Factor (VEGF) expression, and, in 2H11 cells, migration capabilities by wound healing assay. We have found an enhancement of cytotoxicity in 4T1 cells, whereas, in normal 2H11 cells, this effect was not statistically significant. The addition of TMD decreased the production of VEGF after PDT in 2H11 cell line. Our results reveal enhanced effectiveness of 5-ALA-PDT with TMD treatment compared to 5-ALA-PDT or TMD treatment alone. The addition of TMD may be a promising proceeding of the anti-tumor effect of PDT by decreasing the VEGF concentration in the culture medium. Further studies, including testing on different cell lines, are needed to confirm this assumption.
format Online
Article
Text
id pubmed-7664331
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76643312020-11-14 The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line Zduniak, Krzysztof Gdesz-Birula, Katarzyna Woźniak, Marta Duś-Szachniewicz, Kamila Ziółkowski, Piotr Molecules Article Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which is a drug presently used in the treatment of plasma cell myeloma. TMD and PDT share similar modes of action in neoplastic conditions. Using 4T1 murine breast carcinoma and 2H11 murine endothelial cells lines as an experimental tumor model, we tested 5-ALA-PDT and TMD combination in terms of cytotoxicity, apoptosis, Vascular Endothelial Growth Factor (VEGF) expression, and, in 2H11 cells, migration capabilities by wound healing assay. We have found an enhancement of cytotoxicity in 4T1 cells, whereas, in normal 2H11 cells, this effect was not statistically significant. The addition of TMD decreased the production of VEGF after PDT in 2H11 cell line. Our results reveal enhanced effectiveness of 5-ALA-PDT with TMD treatment compared to 5-ALA-PDT or TMD treatment alone. The addition of TMD may be a promising proceeding of the anti-tumor effect of PDT by decreasing the VEGF concentration in the culture medium. Further studies, including testing on different cell lines, are needed to confirm this assumption. MDPI 2020-11-07 /pmc/articles/PMC7664331/ /pubmed/33171718 http://dx.doi.org/10.3390/molecules25215184 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zduniak, Krzysztof
Gdesz-Birula, Katarzyna
Woźniak, Marta
Duś-Szachniewicz, Kamila
Ziółkowski, Piotr
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title_full The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title_fullStr The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title_full_unstemmed The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title_short The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
title_sort assessment of the combined treatment of 5-ala mediated photodynamic therapy and thalidomide on 4t1 breast carcinoma and 2h11 endothelial cell line
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664331/
https://www.ncbi.nlm.nih.gov/pubmed/33171718
http://dx.doi.org/10.3390/molecules25215184
work_keys_str_mv AT zduniakkrzysztof theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT gdeszbirulakatarzyna theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT wozniakmarta theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT dusszachniewiczkamila theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT ziołkowskipiotr theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT zduniakkrzysztof assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT gdeszbirulakatarzyna assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT wozniakmarta assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT dusszachniewiczkamila assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline
AT ziołkowskipiotr assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline